These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32844710)

  • 1. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.
    Chau V; Madan RA; Figg WD
    Cancer Biol Ther; 2020 Oct; 21(10):884-887. PubMed ID: 32844710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
    Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
    Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
    Matsubara N; Nishimura K; Kawakami S; Joung JY; Uemura H; Goto T; Kwon TG; Sugimoto M; Kato M; Wang SS; Pang ST; Chen CH; Fujita T; Nii M; Shen L; Dujka M; Hussain M; de Bono J
    Jpn J Clin Oncol; 2022 May; 52(5):441-448. PubMed ID: 35229141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Matsubara N; de Bono J; Olmos D; Procopio G; Kawakami S; Ürün Y; van Alphen R; Flechon A; Carducci MA; Choi YD; Hotte SJ; Korbenfeld E; Kramer G; Agarwal N; Chi KN; Dearden S; Gresty C; Kang J; Poehlein C; Harrington EA; Hussain M
    Clin Cancer Res; 2023 Jan; 29(1):92-99. PubMed ID: 36318705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
    Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
    PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
    Stopsack KH
    Eur Urol; 2021 Apr; 79(4):442-445. PubMed ID: 33012578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
    Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
    Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective.
    Matsumoto T; Shiota M; Blas L; Eto M
    Cancer Manag Res; 2022; 14():2389-2397. PubMed ID: 35967752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Evans R; Hawkins N; Dequen-O'Byrne P; McCrea C; Muston D; Gresty C; Ghate SR; Fan L; Hettle R; Abrams KR; de Bono J; Hussain M; Agarwal N
    Target Oncol; 2021 Sep; 16(5):613-623. PubMed ID: 34478046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
    Gonzalez D; Mateo J; Stenzinger A; Rojo F; Shiller M; Wyatt AW; Penault-Llorca F; Gomella LG; Eeles R; Bjartell A
    J Pathol Clin Res; 2021 Jul; 7(4):311-325. PubMed ID: 33630412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    Kwon DH; Booth CM; Prasad V
    Eur Urol; 2021 Jun; 79(6):710-712. PubMed ID: 33722420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    Leith A; Ribbands A; Kim J; Last M; Barlow S; Yang L; Ghate SR
    Future Oncol; 2022 Mar; 18(8):937-951. PubMed ID: 35043687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
    Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
    J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.